Work Here?
Industries
AI & Machine Learning
Biotechnology
Company Size
51-200
Company Stage
Series B
Total Funding
$195M
Headquarters
Pasadena, California
Founded
2018
Terray Therapeutics specializes in discovering and developing small molecule drugs by combining experimental techniques with computational methods. The company generates a vast dataset of target-ligand binding measurements, allowing for accurate predictions of molecular properties using AI. Its rapid design-make-test-analyze cycle enables efficient exploration of chemical space, particularly in immunology, while partnerships with pharmaceutical companies expand its reach. The goal is to create effective treatments for diseases through innovative drug discovery.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$195M
Above
Industry Average
Funded Over
3 Rounds
Industry standards
Terray Therapeutics appoints Elliott Levy, MD, to Scientific Advisory Board.
Gilead Sciences has entered a strategic partnership with Terray Therapeutics for the discovery and development of small-molecule therapies across several targets.
Terray will use its tNova platform to develop small molecule compounds for Gilead, which may exclusively license and commercialise them upon exercise of its option
Gilead and Terray Therapeutics announce multi-target research collaboration to discover and develop novel Small Molecule therapies.
BioVie, a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers received $6.67 million of development capital through a private placement.
Find jobs on Simplify and start your career today
Industries
AI & Machine Learning
Biotechnology
Company Size
51-200
Company Stage
Series B
Total Funding
$195M
Headquarters
Pasadena, California
Founded
2018
Find jobs on Simplify and start your career today